Publications by authors named "Mace Rothenberg"

Claim this Profile
D
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop.
Guy Travis Clifton, Mace Rothenberg, Paolo Antonio Ascierto, Glenn Begley, Michael Cecchini

J Immunother Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.
Nadine J McCleary, William S Harmsen, Ellana Haakenstad, James M Cleary, Jeffrey A Meyerhardt, Mace L Rothenberg

JNCI Cancer Spectr· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Price, Cost, and Value of Cancer Medicines: A Pharmaceutical Industry Perspective.
Mace L Rothenberg, Justin McCarthy, Patrick Holmes

Cancer J· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data.
Kerry L Reynolds, Shaily Arora, Ravikumar Komandur Elayavilli, William C Louv, Teilo H Schaller, Mace Rothenberg

J Immunother Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies.
Bo Huang, Lu Tian, Zachary R McCaw, Xiaodong Luo, Enayet Talukder, Mace Rothenberg

Ann Intern Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating anticancer drug development - opportunities and trade-offs.
Sharyl J Nass, Mace L Rothenberg, Rebecca Pentz, Hedvig Hricak, Amy Abernethy

Nat Rev Clin Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.
Tomas G Neilan, Mace L Rothenberg, Laleh Amiri-Kordestani, Ryan J Sullivan, Richard M Steingart

Oncologist· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study.
Bo Huang, Lu Tian, Enayet Talukder, Mace Rothenberg, Dae Hyun Kim

JAMA Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advantages of a Truly Open-Access Data-Sharing Model.
Monica M Bertagnolli, Oliver Sartor, Bruce A Chabner, Mace L Rothenberg, Sean Khozin

N Engl J Med· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
Julia Wilkerson, Kald Abdallah, Charles Hugh-Jones, Greg Curt, Mace Rothenberg

Lancet Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
Huali Wu, Jeffrey R Infante, Vicki L Keedy, Suzanne F Jones, Emily Chan, Mace L Rothenberg

Int J Nanomedicine· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.
Vladimir Lazar, Eitan Rubin, Stephane Depil, Yudi Pawitan, Jean-François Martini, Mace Rothenberg

Oncotarget· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.
Huali Wu, Jeffrey R Infante, Vicki L Keedy, Suzanne F Jones, Emily Chan, Mace L Rothenberg

Eur J Clin Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
Jeffrey R Infante, Vicki L Keedy, Suzanne F Jones, William C Zamboni, Emily Chan, Mace L Rothenberg

Cancer Chemother Pharmacol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
Andrea Wang-Gillam, William P Tew, Mace L Rothenberg, Jakob Dupont, Wendy Cooper

Invest New Drugs· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
Kenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, Nobuyuki Mizunuma, Katsushige Gomi, Mace L Rothenberg

Cancer Med· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
Kenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, Nobuyuki Mizunuma, Po-Huang Lee, Mace L Rothenberg

Clin Colorectal Cancer· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.
Andrea Wang-Gillam, Susanne M Arnold, Ronald M Bukowski, Mace L Rothenberg, Wendy Cooper

Invest New Drugs· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
Laura W Goff, Al B Benson, Patricia M LoRusso, Antoinette R Tan, Jordan D Berlin, Mace L Rothenberg

Invest New Drugs· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma.
Christine H Chung, Paula R Pohlmann, Mace L Rothenberg, Brian B Burkey, Joel Parker

Head Neck· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer.
Emily Chan, Bonnie Lafleur, Mace L Rothenberg, Nipun Merchant, Albert Craig Lockhart

Am J Clin Oncol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.
Igor Puzanov, Wooin Lee, Alice P Chen, M Wade Calcutt, David L Hachey, Mace L Rothenberg

Clin Cancer Res· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
A Craig Lockhart, Mace L Rothenberg, Jakob Dupont, Wendy Cooper, Paul Chevalier

J Clin Oncol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.
Philip A Philip, Margaret Mooney, Deborah Jaffe, Gail Eckhardt, Malcolm Moore, Mace Rothenberg

J Clin Oncol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases.
Peter J O'Brien, Rajeev Ramanathan, Jonathan M Yingling, Jose Baselga, Mace L Rothenberg

Biologics· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis